Akari Therapeutics plc ADS (AKTX) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Akari Therapeutics plc ADS (AKTX) dropped -13.04% to $8.00, trading at 16% of its 52-week range ($3.02 – $33.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Presentation to explore the potential of RNA-splicing payloads to drive broad anti-tumor effects through direct cell killing along with immune activation Satyajit Mitra, Executive Director, Head of Oncology, to discuss d
Gainers Disc Medicine (NASDAQ:IRON) stock moved upwards by 50.4% to $85.51 during Monday's pre-market session. The company's market cap stands at $2.1 billion. DataMEDS AI (NASDAQ:MEDS) shares moved upwards by
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AKTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AKTX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Akari Therapeutics plc ADS (AKTX) ranks #797 by composite RQD confidence (36/100, grade D-) and #840 by equity capitalization ($18.3M). Within this direct 5-issuer industry benchmark cohort, AKTX leads on earnings valuation at N/A trailing P/E, while AKTX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. PBM currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with AKTX at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| AKTX
ACTIVE
Akari Therapeutics plc ADS | D- | 36/100 | — | — | -35.0% | -13.04% | $18.3M | Benchmark Subject |
| KYNB Kyntra Bio Inc. | D | 44/100 | — | 91.4% | -35.0% | -1.48% | $18.8M | /kynb-vs-aktx → |
| COCP Cocrystal Pharma Inc. | D- | 42/100 | — | — | -35.0% | -1.01% | $18.9M | /cocp-vs-aktx → |
| PBM Psyence Biomedical Ltd. | C- | 61/100 | — | — | — | +6.18% | $19.2M | /pbm-vs-aktx → |
| AEON AEON Biopharma Inc. (Class A) | D | 48/100 | — | — | -35.0% | +11.36% | $17.4M | /aeon-vs-aktx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Akari Therapeutics plc ADS (AKTX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 , and -100.0% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$10.6M, and free cash flow of -$10.6M (+15.8% YoY). On the balance sheet, AKTX closed FY2025 with $47.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$17.3M | -$10.6M | -$10.6M | $47.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$19.8M | -$12.6M | -$12.6M | $50.6M | — |
| FY2023 (FY) | 2023-12-31 | $367.9K | -$10.0M | -$16.4M | -$16.4M | — | — |
As of 2026-11-01, Akari Therapeutics plc ADS (NASDAQ: AKTX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $8.00 (-13.04% 1D, market cap $18.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, AKTX ranks #797 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AKTX carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KYNB (Kyntra Bio Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $18.8M) and COCP (Cocrystal Pharma Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $18.9M). Among the 5-stock peer group, AKTX leads on earnings multiple (N/A) while AKTX leads on capital efficiency (-35.0% ROIC).
Per AKTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001541157), Akari Therapeutics plc ADS generated $0 in revenue, -$17.3M in net income, and -$10.6M in free cash flow against $47.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
AKTX last traded at $8.00 (-13.04% on volume of 97,014 shares), positioning the stock -13.79% below its 50-day simple moving average ($9.28) and -11.70% below its 200-day simple moving average ($9.06). Across its 52-week range of $3.02 to $33.60, AKTX sits at the 16.3% percentile with a 14-day RSI of 47.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.00 to $9.00).
Why AKTX Stock dropped -13.04% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.